Prazosin, an α1-adrenoreceptor antagonist, did not reduce nightmare frequency or intensity or improve sleep in military veterans with posttraumatic stress disorder (PTSD), concluded a trial in the New England Journal of Medicine.
The 304 participants with PTSD were randomly assigned to receive placebo or prazosin for 26 weeks—at a dose higher than in most previous trials, the authors noted.
Slomski A. Prazosin May Not Reduce Nightmares in Veterans With PTSD. JAMA. 2018;319(16):1649. doi:10.1001/jama.2018.4741
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: